Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the
"Company") announced that the Company held an extraordinary general
meeting of shareholders today, March 27, 2014, at 14 Hakitor Street,
Haifa Bay 26110, Israel (the "Extraordinary General Meeting"). IVS
Associates, Inc., a leading provider of independent election services,
independently tabulated and certified the voting results of the
Extraordinary General Meeting.
As Taro previously announced, the purpose of the Extraordinary General
Meeting was the ratification of certain resolutions adopted by the
Company's shareholders at its 2013 annual general meetng. These
resolutions were approved and ratified and include the following: (i)
approval of the Company's compensation policy, (ii) approval of
compensation to three of its directors (Dilip Shanghvi, Sudhir Valia and
Kal Sundaram), and (iii) re-election of its external directors (Ilana
Avidov Mor and Dan Biran).
The proposals offered by a shareholder of the Company to elect Mr.
Ben-Ami Rosenfeld and Ms. Adi Bershadsky as External Directors to the
Board of Directors were again not approved.
Taro Pharmaceutical Industries Ltd. is a multinational, science-based
pharmaceutical company, dedicated to meeting the needs of its customers
through the discovery, development, manufacturing and marketing of the
highest quality healthcare products. For further information on Taro
Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com.
[ Back To NFVZone's Homepage ]